

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 22, 2026 (the “**Prospectus**”) issued by Guangdong True Health Medical Technology Development Co., Ltd. (廣東真健康醫療科技開發股份有限公司) (the “**Company**”).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of our Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about our Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. The Company has not intended and does not intend to make any public offer of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

In connection with the Global Offering, China International Capital Corporation Hong Kong Securities Limited, as stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may over-allocate or effect transactions with a view to stabilizing or maintaining the market price of the Offer Shares at a level higher than that which might otherwise prevail in the open market for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be conducted at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end within 30 days of the last day for the lodging of applications under the Hong Kong Public Offering, being Thursday, June 25, 2026. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Cap. 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong). Potential investors should be aware that stabilizing action cannot be taken to support the price of the H Shares for longer than the stabilization period which will begin on the Listing Date and is expected to expire on Saturday, July 25, 2026, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, and demand for the Shares, and therefore the price of the Shares, could fall.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to the terms and conditions set out in the Prospectus. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/or not resident in Hong Kong. Potential investors of the Offer Shares should note that the Joint Sponsors and the Sponsor-Overall Coordinator (for themselves and on behalf of the Hong Kong Underwriters) shall, in its sole and absolute discretion, be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Tuesday, June 30, 2026).



**Guangdong True Health Medical  
Technology Development Co., Ltd.**

**廣東真健康醫療科技開發股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**GLOBAL OFFERING**

<b>Number of Offer Shares under the Global Offering</b>	<b>: 3,564,700 H Shares (subject to the Over-allotment Option)</b>
<b>Number of Hong Kong Offer Shares</b>	<b>: 356,480 H Shares (subject to reallocation)</b>
<b>Number of International Offer Shares</b>	<b>: 3,208,220 H Shares (subject to reallocation and the Over-allotment Option)</b>
<b>Maximum Offer Price</b>	<b>: HK\$135.40 per Offer Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong Dollars and subject to refund)</b>
<b>Nominal Value</b>	<b>: RMB1.00 per H Share</b>
<b>Stock code</b>	<b>: 2697</b>

*Joint Sponsors, Overall Coordinators, Joint Global Coordinators,  
Joint Bookrunners and Joint Lead Managers*



**IMPORTANT NOTICE TO INVESTORS:  
FULLY ELECTRONIC APPLICATION PROCESS**

We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of the Prospectus to the public in relation to the Hong Kong Public Offering.

The Prospectus is available at the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) under the “HKEXnews > New Listings > New Listing Information” section, and our website at [www.truehealth.cn](http://www.truehealth.cn). You may download and print from these website addresses if you want a printed copy of the Prospectus.

To apply for the Hong Kong Offer Shares, you may:

- (i) apply online through the **HK eIPO White Form** service at [www.hkeipo.hk](http://www.hkeipo.hk); or
- (ii) apply electronically through the **HKSCC EIPO** channel and cause HKSCC Nominees to apply on your behalf by instructing your broker or custodian who is a HKSCC Participant to give **electronic application instructions** via HKSCC’s FINI system to apply for the Hong Kong Offer Shares on your behalf.

We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public. The contents of the electronic version of the Prospectus are identical to the printed prospectus as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong).

If you are an **intermediary, broker or agent**, please remind your customers, clients or principals, as applicable, that the Prospectus is available online at the website addresses above.

Please refer to the section headed “How to Apply for Hong Kong Offer Shares” in the Prospectus for further details on the procedures through which you can apply for the Hong Kong Offer Shares electronically.

Your application through the **HK eIPO White Form** service or the **HKSCC EIPO** channel must be for a minimum of 20 Hong Kong Offer Shares and in one of the numbers set out in the table below.

If you are applying through the **HK eIPO White Form** service, you may refer to the table below for the amount payable for the number of Hong Kong Offer Shares you have selected. You must pay the respective maximum amount payable on application in full upon application for Hong Kong Offer Shares.

If you are applying through the **HKSCC EIPO** channel, your broker or custodian may require you to pre-fund your application, in such amount as determined by the broker or custodian, based on the applicable laws and regulations in Hong Kong. You are responsible for complying with any such pre-funding requirement imposed by your broker or custodian with respect to the Hong Kong Offer Shares you applied for.

No. of Hong Kong Offer Shares applied for	Maximum Amount payable <sup>(2)</sup> on application/ successful allotment <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Maximum Amount payable <sup>(2)</sup> on application/ successful allotment <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Maximum Amount payable <sup>(2)</sup> on application/ successful allotment <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Maximum Amount payable <sup>(2)</sup> on application/ successful allotment <i>HK\$</i>
20	2,735.30	300	41,029.66	4,000	547,062.03	50,000	6,838,275.46
40	5,470.63	400	54,706.20	5,000	683,827.55	60,000	8,205,930.55
60	8,205.93	500	68,382.76	6,000	820,593.05	70,000	9,573,585.64
80	10,941.24	600	82,059.30	7,000	957,358.56	80,000	10,941,240.72
100	13,676.56	700	95,735.86	8,000	1,094,124.07	90,000	12,308,895.81
120	16,411.86	800	109,412.40	9,000	1,230,889.58	100,000	13,676,550.90
140	19,147.17	900	123,088.96	10,000	1,367,655.09	120,000	16,411,861.08
160	21,882.47	1,000	136,765.51	20,000	2,735,310.18	140,000	19,147,171.25
180	24,617.80	2,000	273,531.02	30,000	4,102,965.26	160,000	21,882,481.45
200	27,353.10	3,000	410,296.53	40,000	5,470,620.35	178,240 <sup>(1)</sup>	24,377,084.32

*Notes:*

- (1) Maximum number of Hong Kong Offer Shares you may apply for and this is 50% of the Hong Kong Offer Shares initially offered.
- (2) The amount payable is inclusive of brokerage, SFC transaction levy, the Stock Exchange trading fee and AFRC transaction levy. If your application is successful, brokerage will be paid to the Exchange Participants (as defined in the Listing Rules) or to the **HK eIPO White Form** Service Provider (for applications made through the application channel of the **HK eIPO White Form** service) while the SFC transaction levy, the Stock Exchange trading fee and the AFRC transaction levy will be paid to the SFC, the Stock Exchange and the AFRC, respectively.

No application for any other number of the Hong Kong Offer Shares will be considered and any such application is liable to be rejected.

## **APPLICATION FOR LISTING ON THE STOCK EXCHANGE**

We have applied to the Stock Exchange for the listing of, and permission to deal in, the H Shares in issue and to be issued by us pursuant to the Global Offering.

## **STRUCTURE OF THE GLOBAL OFFERING**

The Global Offering comprises:

- (a) the Hong Kong Public Offering of initially 356,480 H Shares (subject to reallocation) in Hong Kong, representing approximately 10.0% of the total number of Offer Shares initially available under the Global Offering; and
- (b) the International Offering of initially 3,208,220 H Shares (subject to reallocation and the Over-allotment Option), representing approximately 90.0% of the total number of Offer Shares initially available under the Global Offering.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed “Structure of the Global Offering” in the Prospectus.

In particular, subject to the requirements under Practice Note 18 of the Listing Rules and the Guide For New Listing Applicants issued by the Stock Exchange (the “**Guide**”), the Overall Coordinators may in their discretion reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Practice Note 18 of the Listing Rules and Chapter 4.14 of the Guide, the maximum total number of Offer Shares that may be allocated to the Hong Kong Public Offering following such reallocation shall not be more than 178,220 Offer Shares, so that the total number of Offer Shares available for subscription under the Hong Kong Public Offering will increase up to 534,700 Offer Shares, representing approximately 15.0% of the number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option) and the final Offer Price shall be fixed at the bottom end of the indicative price range (i.e. HK\$119.30 per Offer Share).

In connection with the Global Offering, the Company is expected to grant the Over-allotment Option to the International Underwriters, which will be exercisable by the Overall Coordinators (for themselves and on behalf of the International Underwriters) at any time from the Listing Date to the 30th day after the last day for lodging applications under the Hong Kong Public Offering, pursuant to which the Company may be required to issue up to an aggregate of 534,700 additional H Shares, representing approximately 15.0% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price under the International Offering, to cover over-allocations in the International Offering, if any. In the event the Over-Allotment Option is exercised, an announcement will be made on the website of the Company at [www.truehealth.cn](http://www.truehealth.cn) and the Stock Exchange’s website at [www.hkexnews.hk](http://www.hkexnews.hk) respectively.

## **PRICING**

The Offer Price will not be more than HK\$135.40 per Offer Share and is currently expected to be not less than HK\$119.30 per Offer Share, unless otherwise announced, as further explained in the section headed “Structure of the Global Offering” in the Prospectus. Applicants for the Hong Kong Offer Shares may be required to pay, on application (subject to application channels), the maximum Offer Price of HK\$135.40 for each Hong Kong Offer Share together with brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%, subject to refund if the Offer Price as finally determined is less than HK\$135.40 per Hong Kong Offer Share.

## **EXPECTED TIMETABLE**

Hong Kong Public Offering commences . . . . . 9:00 a.m. on Monday,  
June 22, 2026

Latest time for completing electronic applications via  
the **HK eIPO White Form** service through  
the designated website at [www.hkeipo.hk](http://www.hkeipo.hk) . . . . . 11:30 a.m. on Thursday,  
June 25, 2026

Application lists of the Hong Kong Public Offering open . . . . . 11:45 a.m. on Thursday,  
June 25, 2026

Latest time for (a) completing full payment of **HK eIPO White Form** applications by effecting internet banking transfer(s) or PPS payment transfer(s) or; (b) giving **electronic application instructions** to HKSCC ..... 12:00 noon on Thursday, June 25, 2026

If you are instructing your **broker** or **custodian** who is a HKSCC Participant to submit **HKSCC EIPO** applications on your behalf through HKSCC’s FINI system in accordance with your instruction, you are advised to contact your **broker** or **custodian** for the latest time for giving such instructions which may be different from the latest time as stated above.

Application lists of the Hong Kong Public Offering close ..... 12:00 noon on Thursday, June 25, 2026

Expected Price Determination Date.....at or before 12:00 noon on Friday, June 26, 2026

Announcement of:

- the final Offer Price;
- the level of indications of interest in the International Offering;
- the level of applications of the Hong Kong Public Offering; and
- the basis of allocation of the Hong Kong Offer Shares

to be published on the website of our Company at [www.truehealth.cn](http://www.truehealth.cn) and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk). ..... no later than 11:00 p.m. on Monday, June 29, 2026

Results of allocations in the Hong Kong Public Offering (with successful applicants’ identification document numbers, where appropriate) to be available through a variety of channels, including:

- from the “Allotment Results” page at designated results of allocations website at [www.tricor.com.hk/ipo/result](http://www.tricor.com.hk/ipo/result) or [www.hkeipo.hk/IPOResult](http://www.hkeipo.hk/IPOResult) with a “search by ID” function from ..... 11:00 p.m. on Monday, June 29, 2026 to 12:00 midnight on Sunday, July 5, 2026
- the Stock Exchange’s website at [www.hkexnews.hk](http://www.hkexnews.hk) and our website at [www.truehealth.cn](http://www.truehealth.cn) which will provide links to the above mentioned websites of the H Share Registrar. .... no later than 11:00 p.m. on Monday, June 29, 2026

- from the allocation results telephone enquiry  
 line by calling +852 3691 8488  
 between 9:00 a.m. and 6:00 p.m. from . . . . . Tuesday, June 30, 2026  
 to Monday, July 6, 2026  
 (excluding Saturday, Sunday and  
 public holidays in Hong Kong)
- for those applying through  
**HKSCC EIPO** channel, you may also check  
 with your broker or custodian from . . . . . 6:00 p.m. on Friday,  
 June 26, 2026

H Share certificates in respect of wholly or partially  
 successful applications to be dispatched or deposited  
 into CCASS in respect of wholly or partially successful  
 applications pursuant to the Hong Kong Public Offering. . . . . on or before Monday,  
 June 29, 2026

**HK eIPO White Form** e-Auto Refund payment  
 instructions/refund checks in respect of wholly or  
 partially successful applications if the final Offer Price  
 is less than the maximum Offer Price per Offer Share  
 initially paid on application (if applicable),  
 or wholly/partially unsuccessful applications to be dispatched . . . . . on or before Tuesday,  
 June 30, 2026

Dealings in the H Shares on the Stock  
 Exchange expected to commence at . . . . . 9:00 a.m. on Tuesday,  
 June 30, 2026

*Note:*

Unless otherwise stated, all times and dates refer to Hong Kong local times and dates.

**SETTLEMENT**

Subject to the granting of the listing of, and permission to deal in, the H Shares on the Stock Exchange and compliance with the stock admission requirements of HKSCC, the H Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the H Shares on the Stock Exchange or any other date HKSCC chooses. Settlement of transactions between participants of the Stock Exchange (as defined in the Listing Rules) is required to take place in CCASS on the second settlement day after any trading day. All activities under CCASS are subject to the General Rules of HKSCC and HKSCC Operational Procedures in effect from time to time. Investors should seek the advice of their stockbroker or other professional advisors for details of the settlement arrangements as such arrangements may affect their rights and interests. All necessary arrangements have been made enabling our H Shares to be admitted into CCASS.

## APPLICATION CHANNELS

**The Hong Kong Public Offering period will begin at 9:00 a.m. on Monday, June 22, 2026 and end at 12:00 noon on Thursday, June 25, 2026 (Hong Kong time).**

To apply for Hong Kong Offer Shares, you may use one of the following application channels:

Application Channel	Platform	Target Investors	Application Time
HK eIPO White Form service	<a href="http://www.hkeipo.hk">www.hkeipo.hk</a>	Investors who would like to receive a physical H Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in your own name.	From 9:00 a.m. on Monday, June 22, 2026 to 11:30 a.m. on Thursday, June 25, 2026, Hong Kong time.  The latest time for completing full payment of application monies will be 12:00 noon on Thursday, June 25, 2026, Hong Kong time.
HKSCC EIPO channel	Your broker or custodian who is a HKSCC Participant will submit a <b>HKSCC EIPO</b> application on your behalf through HKSCC's FINI system in accordance with your instruction.	Investors who would <u>not</u> like to receive a physical H Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in the name of HKSCC Nominees, deposited directly into CCASS and credited to your designated HKSCC Participant's stock account.	Contact your broker or custodian for the earliest and latest time for giving such instructions, as this may vary by broker or custodian.

The **HK eIPO White Form** service and the **HKSCC EIPO** channel are facilities subject to capacity limitations and potential service interruptions and you are advised not to wait until the last day of the application period to apply for Hong Kong Offer Shares.

Please refer to the sections headed "Structure of the Global Offering" and "How to Apply for Hong Kong Offer Shares" in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

Application for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, and on the designated website at [www.hkeipo.hk](http://www.hkeipo.hk) for the **HK eIPO White Form** service.

## PUBLICATION OF RESULTS

The Company expects to announce the results of the final Offer Price, the level of indications of interest in the Global Offering, the level of applications in the Hong Kong Public Offering and the basis of allocations of Hong Kong Offer Shares on the Stock Exchange's website at [www.hkexnews.hk](http://www.hkexnews.hk) and our website at [www.truehealth.cn](http://www.truehealth.cn) by no later than 11:00 p.m. on Monday, June 29, 2026 (Hong Kong time).

The results of allocations and the identification document numbers of successful applicants (where applicable) under the Hong Kong Public Offering will be available through a variety of channels at the times and dates and in the manner specified in the section headed “How to Apply for Hong Kong Offer Shares — B. Publication of Results” in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the conditions of the Global Offering as set out in the section headed “Structure of the Global Offering — Conditions of the Global Offering” in the Prospectus are not satisfied or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee, will be refunded (subject to application channels), without interest.

No temporary document of title will be issued in respect of the H Shares. No receipt will be issued for sums paid on application. H Share certificates will only become valid at 8:00 a.m. on the Listing Date, **provided that** the Global Offering has become unconditional in all respects, and the right of termination described in the section headed “Underwriting” in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. (Hong Kong time) on Tuesday, June 30, 2026, dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. (Hong Kong time) on Tuesday, June 30, 2026. The H Shares will be traded in board lots of 20 H Shares each. The stock code of the H Shares will be 2697.

This announcement is available for viewing on the website of the Company at [www.truehealth.cn](http://www.truehealth.cn) and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).

By order of the Board  
**Guangdong True Health Medical Technology Development Co., Ltd.**  
**Ms. Cheong Hou Iam**  
*Chairperson, Executive Director and General Manager*

Hong Kong, June 22, 2026

*As at the date of this announcement, the Board comprises: (i) Ms. Cheong Hou Iam, Ms. Chen Miaoping and Ms. Guo Jian as executive Directors; (ii) Ms. Mo Jinling as non-executive Director; and (iii) Dr. Liu Lianggang, Mr. Ng Kun Seng Chris and Mr. Ma Jianming as independent non-executive Directors.*